Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment
South African treatment guidelines need to consider viral load, not CD4 count, to achieve greater impact of treatment as prevention: study
Early treatment reduces viral reservoirs but does not prevent rebound
Early antiretroviral therapy may limit gut damage and immune activation
Raltegravir has the edge over two protease inhibitors in three-drug comparison study
Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART
